Storys zum Thema Medikament

Daiichi Sankyo Europe GmbH

Daiichi Sankyo Presents Positive Results of the First Randomised, Controlled Trial of Uninterrupted Oral, Once-daily LIXIANA® (edoxaban) in Atrial Fibrillation Patients Undergoing Catheter Ablation

Munich (ots/PRNewswire) - - ELIMINATE-AF is the first set of data presented in 2019 from the Edoxaban Clinical Research Programme, which will deliver new evidence to support the use of edoxaban in clinical practice - Late-breaking data presented at EHRA 2019, the annual congress of the European Heart Rhythm ...

Novo Nordisk

Ozempic® Superior in Lowering Blood Sugar and Weight Vs Placebo, Both in Combination with SGLT-2 Inhibitors

Bagsværd, Denmark (ots/PRNewswire) - Novo Nordisk today announced publication of results from the SUSTAIN 9 Phase 3b trial in The Lancet Diabetes & Endocrinology. The objective of this 30 week trial was to assess the efficacy and safety of Ozempic® (semaglutide) 1.0 mg when added to SGLT-2 inhibitor (SGLT-2i) ...

Norgine

Important New Trial With Oral FERACCRU® Shows Comparable Efficacy to IV Iron (Ferric Carboxymaltose), Offering a Real Alternative to Hospital Administration for Many Patients[4]

Amsterdam (ots/PRNewswire) - - FERACCRU® (Ferric Maltol) met primary endpoint against Ferinject® (IV Ferric Carboxymaltose (FCM)) and shows clear benefits to Iron Deficiency Anaemia (IDA) patients with inactive Inflammatory Bowel Disease (IBD)4 - FERACCRU® delivered a haemoglobin (Hb) response rate at 12 weeks ...

Hitachi Medical Systems Europe Holding AG

2

Hitachi Medical Systems Europe presents the next generations in Computed Tomography (CT) and Magnetic Resonance Imaging (MRI) at the European Society of Radiology, February 28, 2019

Hitachi Medical Systems Europe Holding AG

3

Good health runs in families / Hitachi Medical Systems Europe welcomes five new family members to the diagnostic ultrasound series at the European Society of Radiology

Daiichi Sankyo Europe GmbH

Daiichi Sankyo Europe and Esperion Announce Validation of the Marketing Authorisation Application (MAA) for Bempedoic Acid and the Bempedoic Acid / Ezetimibe Fixed Dose Combination Tablet

Munich and Ann Arbor, Michigan (ots/PRNewswire) - - Application is based on results of a robust development programme, which demonstrated that bempedoic acid was well tolerated and efficacious for chronic use - Bempedoic acid is a first-in-class, oral, once-daily ATP Citrate Lyase (ACL) inhibitor that reduces ...

Primex Pharmaceuticals

Primex Pharmaceuticals and POA Pharma Sign a Strategic Partnership to Commercialise OZALIN in the Nordic Region

Gothenburg, Sweden and Zug, Switzerland (ots/PRNewswire) - POA Pharma Scandinavia AB, a market-oriented Boutique Healthcare Company, working in close contact with healthcare organizations, professionals and hospitals in Nordic countries and Primex Pharmaceuticals AG, an innovative Anaesthesia pharmaceutical company, ...

Alvogen

Alvogen Launches Generic Equivalent to Suboxone® (Buprenorphine/Naloxone) Sublingual Film

Pine Brook, New Jersey (ots/PRNewswire) - Global pharmaceutical company, Alvogen, has launched its generic equivalent to Suboxone® sublingual film (buprenorphine hydrochloride/naloxone hydrochloride) in the U.S., which will be available in 2mg/0.5 mg, 4mg/1mg, 8 mg/2mg, and 12 mg/3mg strengths. The launch took ...

CartiHeal (2009) Ltd.

CartiHeal Performs First Agili-C(TM) Cartilage Repair Implantation Procedures at Missouri Orthopaedic Institute

Four patients enrolled and operated on by sports medicine surgeon Dr. Seth L. Sherman, MD Kfar Saba, Israel (ots/PRNewswire) - Seth L. Sherman, MD, a sports medicine orthopaedic surgeon at Missouri Orthopaedic Institute, recently became one of the first American surgeons to enroll patients in a clinical research ...

Merck Healthcare Germany GmbH

Merck and GSK Announce Global Alliance to Jointly Develop and Commercialize M7824, a Novel Immunotherapy with Potential in Multiple Difficult-to-Treat Cancers

Not intended for US, Canada or UK-based media Darmstadt, Germany (ots/PRNewswire) - - Eight high priority immuno-oncology clinical development studies ongoing or expected to commence in 2019, including studies in non-small cell lung and biliary tract cancers - Merck will receive an upfront payment of EUR300 million ...

Kanabo Research

Lights Out for Insomnia: New Kanabo Research Study Offers Encouraging Results

Tel Aviv, Israel (ots/PRNewswire) - Kanabo Research (http://www.kanaboresearch.com) is proud to present the promising results of its pre-clinical trial, which brings the company one step closer to providing a safe remedy for insomnia and other sleep disorders, without the risk of dependency or the possibility of an overdose. (Photo: ...

Medasense Biometrics Ltd

Medasense Announces Compatibility with Philips IntelliVue Patient Monitors

Ramat Gan, Israel (ots/PRNewswire) - Medasense Biometrics Ltd., developer of the physiological pain-response monitoring technology (NOL® -- the Nociception Level Index), now supports Philips IntelliVue Patient Monitors for anesthesia and critical care monitoring. (Photo: https://mma.prnewswire.com/media/805789/Medasense_PMD_200_Monitor.jpg ) Commercially available in ...

Daiichi Sankyo Europe GmbH

Daiichi Sankyo Europe Enters into European Licensing Agreement with Esperion for Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet

Munich (ots/PRNewswire) - - Daiichi Sankyo Europe will market oral bempedoic acid and bempedoic acid / ezetimibe combination tablet in the European Economic Area and Switzerland - Bempedoic acid is a first-in-class, oral, once-daily ATP Citrate Lyase (ACL) inhibitor that reduces cholesterol and fatty acid synthesis ...

Sophia Genetics

SOPHiA GENETICS Raises $77 Million to Accelerate the Democratization of Data-Driven Medicine

San Francisco (ots/PRNewswire) - SOPHiA GENETICS, a leading health tech company, announced today the closing of a $77 million investment round to accelerate the democratization of Data-Driven Medicine. The round was led by Generation Investment Management, a pioneer of sustainable investing, with offices in London and San Francisco. Generation were joined by Idinvest ...

NORGINE B.V. and KOREA PHARMA CO., LTD.

NORGINE B.V. and KOREA PHARMA CO., LTD. Enter Into Exclusive Licence Agreement for the Commercialisation of PLENVU® in the Republic of Korea

Amsterdam and Seoul, South Korea (ots/PRNewswire) - - Norgine to receive a significant upfront payment and undisclosed sums in sales milestones along with double-digit percentage royalties - Norgine retains full commercial rights to PLENVU® in all unlicensed countries NORGINE B.V. (Norgine), a leading European ...

Merck Healthcare Germany GmbH

Merck Announces EMA Orphan Drug Designation for Bifunctional Immunotherapy M7824 in Biliary Tract Cancer

Darmstadt, Germany (ots/PRNewswire) - The information contained is not intended for distribution in the USA, Canada or the UK - European Medicine Agency (EMA) grants M7824, an investigational bifunctional immunotherapy, orphan drug designation in biliary tract cancer (BTC) - EMA orphan drug designation for M7824 in ...

Merck Healthcare Germany GmbH

Merck Announces FDA Orphan Drug Designation for Bifunctional Immunotherapy M7824 in Biliary Tract Cancer

Darmstadt, Germany (ots/PRNewswire) - The information contained is not intended for distribution in the USA, Canada or the UK - FDA grants M7824, an investigational bifunctional immunotherapy, orphan drug designation in biliary tract cancer - First regulatory designation for M7824 following recent presentation of ...

Hitachi Medical Systems Europe Holding AG

2

Hitachi Medical Systems Europe introduces the third generation of non-invasive intracardiac blood flow visualization technology, at EuroEcho Imaging 2018

Kyowa Kirin International PLC

Kyowa Kirin Announces POTELIGEO® Receives Marketing Authorisation in Europe for the Treatment of Mycosis Fungoides and Sézary Syndrome

Tokyo (ots/PRNewswire) - POTELIGEO will be the first biologic agent targeting CCR4 to be available for patients in Europe. Kyowa Hakko Kirin Co., Ltd., (Kyowa Kirin) announces today that it has received a European Commission decision granting a marketing authorisation to POTELIGEO® (Generic name: mogamulizumab), a ...

Zentiva

Zentiva and PHOENIX Form Strategic Partnership in Europe

Prague (ots/PRNewswire) - Zentiva and PHOENIX joined forces this week for an inaugural Annual Partnership meeting in Prague to kick off a strategic partnership between the two healthcare companies in Europe. (Logo: https://mma.prnewswire.com/media/788903/Zentiva_Logo.jpg ) "At PHOENIX group we believe that Zentiva is an excellent fit for partnering at European level, thanks to their strong heritage, broad portfolio of ...

Merck Healthcare Germany GmbH

Merck and Pfizer Provide Update on Avelumab in Platinum-Resistant/Refractory Ovarian Cancer

Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for US, Canada and UK-based media Merck and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combination with pegylated liposomal doxorubicin (PLD), a type of chemotherapy, compared ...

Royal Philips

Philips Debuts Noninvasive Ventilator With High Flow Therapy to Improve Patient Care

Amsterdam (ots/PRNewswire) - - Philips V60 Plus ventilator receives CE Mark, expands on Philips' commitment and leadership in hospital respiratory care - New comprehensive solution enhances clinician workflow and maximizes equipment efficiency to help drive earlier intervention in respiratory distress Royal Philips (https://www.philips.com/) (NYSE: PHG) (AEX: PHIA), a ...

Inceptua

Head of Global Patient Access Joins Inceptua

Luxembourg (ots/PRNewswire) - Inceptua Group today announces that Clive Whitcher joins Inceptua as Vice President, Head of Global Patient Access. (Logo: https://mma.prnewswire.com/media/739136/Inceptua_Group_Logo.jpg ) "Clive joining the team to focus on patient access strengthens our commercialization capabilities, offering even greater support to our partner companies as they try to reach patients in need," says Alan ...

Primary Care Diabetes Europe (PCDE)

Primary Care Diabetes Europe Issues Call to Action Against Clinical Inertia in the Treatment of Type-2 Diabetes

Ekeren, Belgium (ots/PRNewswire) - Research identifies lack of primary care physician adherence to treatment guidelines among the challenges to optimal care for patients with type-2 diabetes Primary Care Diabetes Europe (PCDE) today issued a call to action (https://www.pcdeurope.org/early-action/) challenging ...

Schweizerischer Nationalfonds / Fonds national suisse

Latsis Prize 2018: Andrea Ablasser unlocks the secret of rapid virus defence

COMPASS Pathways

COMPASS Pathways Receives FDA Breakthrough Therapy Designation for Psilocybin Therapy for Treatment-resistant Depression

London (ots/PRNewswire) - COMPASS Pathways (https://compasspathways.com/), a life sciences company dedicated to accelerating patient access to evidence-based innovation in mental health, has received Breakthrough Therapy designation from the US Food and Drug Administration (FDA) for its psilocybin therapy for ...

Janssen Pharmaceutica

New Phase 2 Data Show Stelara® (ustekinumab) Sustained Improvement in Disease Activity in Adults With Systemic Lupus Erythematosus Through One Year

Beerse, Belgium (ots/PRNewswire) - - Janssen presents one-year data from continued Phase 2 lupus study during plenary session at 2018 American College of Rheumatology (ACR) / Association for Rheumatology Health Professionals (ARHP) Annual Meeting The Janssen Pharmaceutical Companies of Johnson & Johnson today ...

Merck Healthcare Germany GmbH

Merck Inaugurates State-of-the-art Pharma Packaging Center in Darmstadt

Darmstadt, Germany (ots/PRNewswire) - - Expansion of the pharma manufacturing site at Merck's headquarters supports growth of current and future portfolio of pharma medicines - New building dedicated to the packaging and shipping of Merck's pharma medicines in more than 90 countries - EUR63 million investment in new packaging center is part of wider EUR1 billion ...

Janssen Pharmaceutica

Janssen to highlight data from broad rheumatology portfolio at the 2018 Annual meeting of the American College of Rheumatology

Beerse, Belgium (ots/PRNewswire) - - One-year results from the Phase 2 study evaluating STELARA® (ustekinumab) in patients with active systemic lupus erythematosus featured in a plenary presentation - 13 presentations from approved and pipeline products provide real-world treatment and disease insights across ...

Merck Healthcare Germany GmbH

BAVENCIO® (avelumab) Plus INLYTA® (axitinib) Significantly Improved Progression-Free Survival in Previously Untreated Patients With Advanced Renal Cell Carcinoma in Phase III Study

Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for US, Canada and UK-based media - First positive Phase III immunotherapy trial in combination with a tyrosine kinase inhibitor (TKI) in any tumor type - Results significant in both PDL1+ and all-comer populations - Alliance plans to pursue a ...